M
Maria Antonia Coccia-Portugal
Publications - 6
Citations - 1396
Maria Antonia Coccia-Portugal is an academic researcher. The author has contributed to research in topics: Lapatinib & Trastuzumab. The author has an hindex of 3, co-authored 3 publications receiving 1248 citations.
Papers
More filters
Journal ArticleDOI
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.
José Baselga,José Baselga,Ian Bradbury,Holger Eidtmann,Serena Di Cosimo,Serena Di Cosimo,Evandro de Azambuja,Claudia Aura,Henry L. Gomez,Phuong Dinh,Karine Fauria,Veerle Van Dooren,Gursel Aktan,Aron Goldhirsch,Tsai Wang Chang,Zsolt Horváth,Maria Antonia Coccia-Portugal,Julien Domont,Ling Min Tseng,Georg Kunz,Joohyuk Sohn,Vladimir Semiglazov,Guillermo Lerzo,Marketa Palacova,Volodymyr Probachai,Lajos Pusztai,Michael Untch,Richard D. Gelber,Martine Piccart-Gebhart +28 more
TL;DR: Dual inhibition of Her2 might be a valid approach to treatment of HER2-positive breast cancer in the neoadjuvant setting, and the two anti-HER2 agents given together would be better than single-agent therapy.
Journal ArticleDOI
18F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO
Geraldine Gebhart,Cristina Gamez,Eileen Holmes,Javier Robles,Camilo Garcia,Montserrat Cortes,Evandro de Azambuja,Karine Fauria,Veerle Van Dooren,Gursel Aktan,Maria Antonia Coccia-Portugal,Sung-Bae Kim,Peter Vuylsteke,Hervé Cure,Holger Eidtmann,José Baselga,José Baselga,Martine Piccart,Patrick Flamen,Serena Di Cosimo +19 more
TL;DR: Early metabolic assessment using 18F-FDG PET/CT can identify patients with an increased likelihood of pathologic complete response (pCR) to neoadjuvant lapatinib, trastuzumab, or their combination when given with chemotherapy.
Journal ArticleDOI
RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial.
Debora Fumagalli,David Venet,Michail Ignatiadis,Hatem A. Azim,Marion Maetens,Françoise Rothé,Roberto Salgado,Ian Bradbury,Lajos Pusztai,Nadia Harbeck,Henry L. Gomez,Tsai Wang Chang,Maria Antonia Coccia-Portugal,Serena Di Cosimo,Evandro de Azambuja,Lorena de la Peña,Paolo Nuciforo,Jan C. Brase,Jens Huober,José Baselga,Martine Piccart,Sherene Loi,Christos Sotiriou +22 more
TL;DR: The expression of ERBB2/HER2 was the most significant predictor of pCR, followed by HER2-enriched subtype, ESR1, treatment arm, ER immunohistochemical analysis scores, Genomic Grade Index, immune, proliferation, and AKT/mTOR GSs.
Journal ArticleDOI
Predictive role of CD36 expression in HER2-positive breast cancer patients receiving neoadjuvant trastuzumab.
Francesca Ligorio,Serena Di Cosimo,Paolo Verderio,Chiara Maura Ciniselli,Sara Pizzamiglio,Lorenzo Castagnoli,Matteo Dugo,Barbara Galbardi,Roberto Salgado,Sherene Loi,Stefan Michiels,Tiziana Triulzi,Elda Tagliabue,Sarra El-Abed,Miguel A. Izquierdo,Evandro de Azambuja,Paolo Nuciforo,Jens Huober,Luca Moscetti,Wolfgang Janni,Maria Antonia Coccia-Portugal,Paola Antonia Corsetto,Antonino Belfiore,Daniele Lorenzini,Maria Grazia Daidone,Andrea Vingiani,Luca Gianni,Serenella M. Pupa,Giampaolo Bianchini,Giancarlo Pruneri,Claudio Vernieri +30 more
TL;DR: High CD36 expression predicts worse clinical outcomes in early-stage HER2+ BC treated with trastuzumab-based neoadjuvant therapy.
Journal ArticleDOI
Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer.
Paolo Nuciforo,Jonathan N. Townend,Martine Piccart,Shona Fielding,Panagiota Gkolfi,Sarra El-Abed,Evandro de Azambuja,G. Werutsky,Judith M Bliss,Volker Moebus,Marco Colleoni,Alvaro Moreno Aspitia,Henry L. Gomez,Andrea Gombos,Maria Antonia Coccia-Portugal,Ling Ming Tseng,G. Kunz,Guillermo Lerzo,Joohyuk Sohn,Vladimir Semiglazov,Cristina Saura,Judith R. Kroep,Antonella Ferro,David Cameron,Richard D. Gelber,Jens Huober,Serena Di Cosimo +26 more
TL;DR: In this paper , the authors investigated the long-term impact on survival of the additional increase in pathological complete response (pCR) compared to single blockade when added to chemotherapy and found that women who achieved a pCR had improved EFS (hazard ratio 0.48, 95% CI, 0.31-0.73) and overall survival (OS).